Journey Biosciences launches NaviDKD™ for people with diabetes to predict long-term kidney complications

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.

Metadata

Provider:

PR Newswire

Retrieved on:

Thursday, December 1, 2022

Information

Tags:

Diagnosis, Kidney disease, Kidney, Compass, Multimedia, Risk, Certification, Biotechnology, DKD, Biomarker, CLIA, Diabetes, LDT, Pharmaceutical industry

Geotags:

NEW HAMPSHIRE

⚠ partially generated by AI ↴

Organisation:

JOURNEY BIOSCIENCES, JOURNEY BIOSCIENCES, INC.

Summary

Key Points:

LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc. , a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.
NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear.
Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.
"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences.

Journey Biosciences launches NaviDKD™ for people with diabetes to predict long-term kidney complications

First and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventative action and improve outcomes.

LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.

The only screening technology to provide early read on the risk of developing kidney disease for people with diabetes

NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.

"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."

Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.

Both healthcare professionals and people with diabetes can learn more and request NaviDKD at www.journeybio.life.

About Journey Biosciences

Journey Biosciences is a US-based biotechnology company dedicated to fundamentally improving diabetes care. We are focused on identifying blood-based predictive biomarkers and developing clinically validated, laboratory developed tests (LDTs) that identify and rate a person's risk level for developing complications from diabetes. Learn more at www.journeybio.life.

Know Your Risk. Change Your Life. ™

To access the Journey Biosciences media kit, visit journeybio.life/media

View original content to download multimedia:https://www.prnewswire.com/news-releases/journey-biosciences-launches-navidkd-for-people-with-diabetes-to-predict-long-term-kidney-complications-301691995.html

SOURCE Journey Biosciences, Inc.